BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

Philochem AG, part of the Philogen Group (MIL:PHIL), and RayzeBio, a subsidiary of Bristol-Myers Squibb (NYSE:BMY), announced ...

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 15 best stocks to invest in for an 18 year old. On June 10, ...

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in ...

Philochem to license worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer to RayzeBio: Otelfingen, Switzerland Thur ...

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

ZURICH, Switzerland and OXFORD, United Kingdom and MONROE TOWNSHIP, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Philochem AG, a wholly owned subsidiary of Philogen S.p.A ...

The positions in the table below reflect the Philochem's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

Novel ultra-high affinity ligand OncoFAP targets Fibroblast Activation Protein (FAP), associated with a variety of solid tumors Licensing agreement between Philochem and Blue Earth Diagnostics ...